232 related articles for article (PubMed ID: 6505358)
1. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
Ellard GA
Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
[TBL] [Abstract][Full Text] [Related]
2. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.
Ellard GA
Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):610-25. PubMed ID: 773583
[TBL] [Abstract][Full Text] [Related]
3. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
[TBL] [Abstract][Full Text] [Related]
4. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
Singh SP; Pande JN; Khilnani GC; Kailash S
Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
6. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
Ellard GA; Gammon PT
Br J Clin Pharmacol; 1977 Feb; 4(1):5-14. PubMed ID: 843424
[TBL] [Abstract][Full Text] [Related]
7. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
Ylitalo P; Auterinen L; Marttinen A; Koivula T
Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
[TBL] [Abstract][Full Text] [Related]
8. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
9. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska C; Hellstrom PE; Fröseth B
Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
[TBL] [Abstract][Full Text] [Related]
10. Determination of the acetylator phenotype using matrix isoniazid.
Ellard GA; Gammon PT; Titinen H
Tubercle; 1975 Sep; 56(3):203-9. PubMed ID: 1216339
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.
Mason E; Russell DW
Bull World Health Organ; 1971; 45(5):617-24. PubMed ID: 5316954
[TBL] [Abstract][Full Text] [Related]
12. [Incidence of hepatotoxic side effects during antituberculous therapy (INH, RMP, EMB) in relation to the acetylator phenotype (author's transl)].
Musch E; Eichelbaum M; Wang JK; von Sassen W; Castro-Parra M; Dengler HJ
Klin Wochenschr; 1982 May; 60(10):513-9. PubMed ID: 7098379
[TBL] [Abstract][Full Text] [Related]
13. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.
Ellard GA
Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429
[No Abstract] [Full Text] [Related]
14. Incidence of isoniazid acetylation phenotypes in North Indians.
Gupta RC; Nair CR; Jindal SK; Malik SK
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
[TBL] [Abstract][Full Text] [Related]
15. [Value of determining plasma INH during antitubercular treatment. Retrospective analysis of 204 cases].
Cheminat JC; Paire M; Lavarenne J; Ducarrouge C; Molina C
Rev Fr Mal Respir; 1983; 11(6):867-73. PubMed ID: 6669797
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.
Yamamoto T; Suou T; Hirayama C
Hepatology; 1986; 6(2):295-8. PubMed ID: 3957235
[TBL] [Abstract][Full Text] [Related]
17. The incidence of the acetylator phenotype of isoniazid in healthy and in pulmonary tuberculosis subjects in Bihar.
Sinha CP; Sinha S; Sinha KP
J Assoc Physicians India; 1978 May; 26(5):353-60. PubMed ID: 730714
[No Abstract] [Full Text] [Related]
18. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.
Sarma GR; Immanuel C; Kailasam S; Narayana AS; Venkatesan P
Am Rev Respir Dis; 1986 Jun; 133(6):1072-5. PubMed ID: 3717759
[TBL] [Abstract][Full Text] [Related]
19. [Isoniazid acetylation in a group of Tunisian patients. Report of 620 patients].
Mehiri BR; Zouaoui A; Chérif J; Ourari B; Daghfous R; Oueslati MH; Louzir B; Daghfous J; Chelbi B; Béji M
Tunis Med; 2005 Jul; 83(7):385-9. PubMed ID: 16220693
[TBL] [Abstract][Full Text] [Related]
20. Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body-weight and surface-area-related dosages of the drug.
Sarma GR; Kailasam S; Datta M; Loganathan GK; Rahman F; Narayana AS
Indian Pediatr; 1990 Feb; 27(2):134-42. PubMed ID: 2361757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
